Septic Shock Clinical Trial
Official title:
Multiple Electrolyte Solution vs. Saline in Pediatric Septic Shock
Verified date | December 2021 |
Source | All India Institute of Medical Sciences, New Delhi |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Fluid resuscitation is the cornerstone of pediatric shock management; current practices of fluid resuscitation in children are not evidence based. Normal saline is the preferred crystalloid recommended during initial resuscitation in shock, as the incidence of hyponatremia is lower with normal saline compared to all other fluids available and commonly used. However, normal saline has its own set of undesired physicochemical actions. Emerging data strongly indicate the increased incidence of hyperchloremia, metabolic acidosis and consequently, acute kidney injury associated with infusion of large volumes of normal saline. Balanced salt solutions or crystalloids, which have composition resembling plasma but lower chloride concentrations than normal saline, clearly decrease the risk of hyperchloremia and metabolic acidosis in adult as well as pediatric studies when used during the peri-operative period. The results favored balanced solutions in comparison to normal saline. Recent systematic reviews comparing balanced or buffered versus non-buffered fluids for surgery in adults favored the former solution as the metabolic derangements were less with the use of this type of fluid. In adult patients, the two solutions have been compared in various other settings as well such as in traumatic brain injury and in shock. The results favored balanced solutions in comparison to normal saline. However, in the non-surgical setting there is a paucity of evidence on the use of these solutions in children with shock and more evidence needs to be generated to support or refute the use of this fluid as compared to normal saline. Given this background, the investigators decided to compare the effect of two solutions on the incidence of acute kidney injury in children resuscitated with either of the two fluids. Children receiving at least one fluid bolus at 20 ml/kg in the first hour would be enrolled and followed up for the proposed outcome variables. The investigators plan to enroll 708 patients over a period of 3 years. The investigators believe that the proposed study will provide answer to the research question of which of the fluids could be preferred for resuscitation.
Status | Completed |
Enrollment | 708 |
Est. completion date | January 15, 2020 |
Est. primary completion date | January 15, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Months to 15 Years |
Eligibility | Inclusion Criteria: - Children 2 month to = 15 years with features of septic shock - defined as children who have a suspected infection manifested by hypothermia or hyperthermia and have at least two clinical signs of decreased perfusion with or without hypotension Exclusion Criteria: - Children receiving fluid boluses before enrollment - Children with cardiogenic shock - Known patient with chronic kidney disease with baseline deranged renal function (eGFR < 90 ml/1.73 m2/min) - Severe malnutrition - Children whose parents refuse to give an informed consent |
Country | Name | City | State |
---|---|---|---|
India | St Johns Medical College and Hospital | Bengaluru | Karnataka |
India | PGIMER | Chandigarh | |
India | All India Institute of Medical Sciences | New Delhi | Delhi |
India | JIPMER | Puducherry |
Lead Sponsor | Collaborator |
---|---|
All India Institute of Medical Sciences, New Delhi | Jawaharlal Institute of Postgraduate Medical Education & Research, Postgraduate Institute of Medical Education and Research, St Johns Medical College Hospital, Bangalore, India |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety outcome 1 | New or progressive AKI requiring dialysis (serious adverse event) | From the time of randomization/intervention to 7 days of admission | |
Other | Safety outcome 2 | IN-ICU mortality in patients with AKI (serious adverse event) | From the time of randomization/intervention to mortality | |
Other | Safety outcome 3 | Infusion related adverse events- fever, rash, extravasation, hypervolemia/fluid overload | From the time of initiating the bolus to its completion | |
Primary | New or progressive acute kidney injury defined as increase in serum creatinine by > 0.3mg/dL within 48 hours or to 1.5 times baseline or more within the last 7 days or urine output less than 0.5 mL/kg/h for 6 hours | Incidence of new or progressive AKI in first 7 days after randomization/ intervention | From the time of randomization/intervention to 7 days of admission | |
Secondary | Proportion of patients with serum chloride levels > 108 meq/L at admission, 6, 24, 48 and 72 hours | Incidence of hyperchloremia | At 6, 24, 48 and 72 hours after randomization | |
Secondary | Number of fluid boluses received in the first 6 hours after randomization | Total number of fluid boluses received in the first 6 hours after randomization/intervention | From the time of randomization to 6 hours | |
Secondary | Total fluids received in the first 24 hours, 24-48 hours and 48-72hrs in ml/kg after randomization | Total fluids received in first 24 hours, 24-48 hours and 48-72 hours | From the time of randomization to 72 hours | |
Secondary | Mortality (serious adverse event) | Death during ICU course | From the time of randomization till death or discharge from ICU, whichever came first assessed upto 100 days | |
Secondary | Time to resolution of AKI | Time taken for resolution of AKI | From the time of onset of AKI after randomization till death or discharge from hospital, whichever came first assessed upto 100 days | |
Secondary | SOFA scores at 24 and 48 hours after randomization | Comparison of SOFA scores in both groups at 24 hours and 48 hours after randomization | At 24 and 48 hours after randomization | |
Secondary | PELOD scores at 24 and 48 hours after randomization | Comparison of PELOD scores in both groups at 24 hours and 48 hours after randomization | At 24 and 48 hours after randomization | |
Secondary | Incidence of metabolic acidosis at 6, 24, 48 and 72 hours after randomization | Comparison of number of children in both groups with acidosis at 6, 24, 48 and 72 hours after randomization | At admission and at 6, 24, 48 and 72 hours after randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Completed |
NCT02306928 -
PK Analysis of Piperacillin in Septic Shock Patients
|
N/A | |
Completed |
NCT02079402 -
Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care
|
Phase 4 |